People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

People with CTEPH and higher PAWP may see fewer gains from BPA, though safety and survival remain similar, a study shows.

Scientists found altered activity of the PUM1 protein plays a key role in pulmonary hypertension development, making it a PH ...

Tiakis Biotech is preparing for a Phase 2 U.S. trial of tiprelestat for PAH after completing a data package required for ...

This holiday season, columnist Anna Jeter is searching for some silver linings in her life and to try to be grateful, despite ...

A mouse study shows overproduction of the naturally occurring hormone adrenomedullin reduced lung injury and PH in ...

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Scientists identified two proteins as biomarkers of CTEPH severity and progression, a discovery that could pave the way for future treatment.

Merck Canada said it has successfully completed negotiations on its PAH therapy Winrevair with the pan‑Canadian Pharmaceutical Alliance.